S&P 500   3,951.57
DOW   32,244.58
QQQ   305.97
5 Tech Stocks With Bank-Like Dividend Yields
BREAKING: Tiny biotech successfully treats blindness (Ad)
First Republic Bank Hits New Low, Dimon Pushes for More Cash
GBTC: The One Place to Buy Bitcoin for 58 Cents on the Dollar
This Trade Strategy Outpaces Almost Anything (Ad)pixel
Mullen Automotive: Investment? No. Compelling Speculation, Yes 
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
This Trade Strategy Outpaces Almost Anything (Ad)pixel
Which Gold Stocks Can Help You Hedge Bank Exposure?
General Mills Retreats To Buy Zone Ahead Of Earnings 
S&P 500   3,951.57
DOW   32,244.58
QQQ   305.97
5 Tech Stocks With Bank-Like Dividend Yields
BREAKING: Tiny biotech successfully treats blindness (Ad)
First Republic Bank Hits New Low, Dimon Pushes for More Cash
GBTC: The One Place to Buy Bitcoin for 58 Cents on the Dollar
This Trade Strategy Outpaces Almost Anything (Ad)pixel
Mullen Automotive: Investment? No. Compelling Speculation, Yes 
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
This Trade Strategy Outpaces Almost Anything (Ad)pixel
Which Gold Stocks Can Help You Hedge Bank Exposure?
General Mills Retreats To Buy Zone Ahead Of Earnings 
S&P 500   3,951.57
DOW   32,244.58
QQQ   305.97
5 Tech Stocks With Bank-Like Dividend Yields
BREAKING: Tiny biotech successfully treats blindness (Ad)
First Republic Bank Hits New Low, Dimon Pushes for More Cash
GBTC: The One Place to Buy Bitcoin for 58 Cents on the Dollar
This Trade Strategy Outpaces Almost Anything (Ad)pixel
Mullen Automotive: Investment? No. Compelling Speculation, Yes 
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
This Trade Strategy Outpaces Almost Anything (Ad)pixel
Which Gold Stocks Can Help You Hedge Bank Exposure?
General Mills Retreats To Buy Zone Ahead Of Earnings 
S&P 500   3,951.57
DOW   32,244.58
QQQ   305.97
5 Tech Stocks With Bank-Like Dividend Yields
BREAKING: Tiny biotech successfully treats blindness (Ad)
First Republic Bank Hits New Low, Dimon Pushes for More Cash
GBTC: The One Place to Buy Bitcoin for 58 Cents on the Dollar
This Trade Strategy Outpaces Almost Anything (Ad)pixel
Mullen Automotive: Investment? No. Compelling Speculation, Yes 
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
This Trade Strategy Outpaces Almost Anything (Ad)pixel
Which Gold Stocks Can Help You Hedge Bank Exposure?
General Mills Retreats To Buy Zone Ahead Of Earnings 
NASDAQ:CTXR

Citius Pharmaceuticals - CTXR Stock Forecast, Price & News

$0.98
-0.04 (-3.94%)
(As of 03/20/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.96
$1.03
50-Day Range
$0.92
$1.42
52-Week Range
$0.77
$2.01
Volume
675,985 shs
Average Volume
882,003 shs
Market Capitalization
$142.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

CTXR stock logo

About Citius Pharmaceuticals (NASDAQ:CTXR) Stock

Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.

Receive CTXR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Citius Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CTXR Stock News Headlines

Citius Pharmaceuticals, Inc. (CTXR)
This Trade Strategy Outpaces Almost Anything
Despite the volatility of the last few years, this reclusive millionaire hasn’t closed a losing trade since July 2016. He just plugs away, executing what may be the most effective investment strategy on Earth. He turned $50K into $5.3M! Want to see the details? Click HERE to watch it for yourself. pixel
My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
Citius Pharmaceuticals, Inc. to Present at the H....
See More Headlines
Receive CTXR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Citius Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CTXR Company Calendar

Last Earnings
12/22/2022
Today
3/20/2023
Next Earnings (Estimated)
5/11/2023
Fiscal Year End
9/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CTXR
Fax
N/A
Employees
15
Year Founded
N/A

Profitability

Net Income
$-33,640,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.71 per share

Miscellaneous

Free Float
123,442,000
Market Cap
$142.72 million
Optionable
Not Optionable
Beta
1.40

Key Executives

  • Leonard L. Mazur
    Chairman, Chief Executive Officer & Secretary
  • Gary F. Talarico
    Executive Vice President-Operations
  • Jaime Bartushak
    Chief Financial & Business Officer
  • Alan Lader
    SVP, Head-Clinical Operations & Quality Assurance
  • Myron S. Czuczman
    Chief Medical Officer & Executive Vice President













CTXR Stock - Frequently Asked Questions

How have CTXR shares performed in 2023?

Citius Pharmaceuticals' stock was trading at $0.79 on January 1st, 2023. Since then, CTXR stock has increased by 23.5% and is now trading at $0.9758.
View the best growth stocks for 2023 here
.

When is Citius Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023.
View our CTXR earnings forecast
.

How were Citius Pharmaceuticals' earnings last quarter?

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) posted its earnings results on Thursday, December, 22nd. The company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by $0.01.

When did Citius Pharmaceuticals' stock split?

Shares of Citius Pharmaceuticals reverse split on the morning of Friday, June 9th 2017. The 1-15 reverse split was announced on Thursday, June 8th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 8th 2017. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Citius Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Citius Pharmaceuticals investors own include Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Novan (NOVN), ADMA Biologics (ADMA), SCYNEXIS (SCYX), Aeterna Zentaris (AEZS), CBL & Associates Properties (CBL), KushCo (KSHB) and Gran Tierra Energy (GTE).

What is Citius Pharmaceuticals' stock symbol?

Citius Pharmaceuticals trades on the NASDAQ under the ticker symbol "CTXR."

Who are Citius Pharmaceuticals' major shareholders?

Citius Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Geode Capital Management LLC (0.91%), Millennium Management LLC (0.38%), GSA Capital Partners LLP (0.34%), Renaissance Technologies LLC (0.28%), HighTower Advisors LLC (0.13%) and Morgan Stanley (0.08%).
View institutional ownership trends
.

How do I buy shares of Citius Pharmaceuticals?

Shares of CTXR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Citius Pharmaceuticals' stock price today?

One share of CTXR stock can currently be purchased for approximately $0.98.

How much money does Citius Pharmaceuticals make?

Citius Pharmaceuticals (NASDAQ:CTXR) has a market capitalization of $142.72 million. The company earns $-33,640,000.00 in net income (profit) each year or ($0.18) on an earnings per share basis.

How can I contact Citius Pharmaceuticals?

Citius Pharmaceuticals' mailing address is 11 Commerce Drive First Floor, Cranford NJ, 07016. The official website for the company is www.citiuspharma.com. The company can be reached via phone at (908) 967-6677 or via email at ir@citiuspharma.com.

This page (NASDAQ:CTXR) was last updated on 3/21/2023 by MarketBeat.com Staff